Evidence map›Paper›PMID 42812828›Full record

ArticleRSC advances2026

The novel [

Juliana Carron, Gabriella Fraiji Melo, Fábio Fernando Alves da Silva, Flávio Lopes Alves, Maria Eduarda de Oliveira Amaro Santos, Vânia Pereira de Castro Rodrigues, Arif Ali, Gilberto Carlos Franchi, João Ernesto de Carvalho, Ana Lucia Tasca Gois Ruiz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juliana CarronLaboratory of Cancer Genetics, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.ORCID https://orcid.org/0000-0002-1108-6343
Gabriella Fraiji MeloSanta Casa de São Paulo School of Medical Sciences São Paulo Brazil.
Fábio Fernando Alves da SilvaLaboratory of Cancer Genetics, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.ORCID https://orcid.org/0009-0002-6502-9317
Flávio Lopes AlvesSanta Casa de São Paulo School of Medical Sciences São Paulo Brazil.
Maria Eduarda de Oliveira Amaro SantosLaboratory of Cancer Genetics, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.
Vânia Pereira de Castro RodriguesDivision of Nuclear Medicine, University of Campinas Campinas São Paulo Brazil.
Arif AliLaboratory of Cancer Genetics, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.ORCID https://orcid.org/0000-0003-1763-1362
Gilberto Carlos FranchiIntegrated Center for Childhood Oncohematological Research, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.
João Ernesto de CarvalhoSchool of Pharmaceutical Sciences, University of Campinas Campinas São Paulo Brazil.
Ana Lucia Tasca Gois RuizSchool of Pharmaceutical Sciences, University of Campinas Campinas São Paulo Brazil.
Leonardo Lima FuscaldiSanta Casa de São Paulo School of Medical Sciences São Paulo Brazil.ORCID https://orcid.org/0000-0001-7864-1324
Luciana MalavoltaSanta Casa de São Paulo School of Medical Sciences São Paulo Brazil.ORCID https://orcid.org/0000-0002-5199-5760
Carmen Silvia Passos LimaLaboratory of Cancer Genetics, School of Medical Sciences, University of Campinas Campinas São Paulo Brazil.ORCID https://orcid.org/0000-0002-1314-2345

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GB) is the most aggressive primary brain tumor. Patient survival remains poor, with current therapies bringing no improvements, and the assessment of therapy response and tumor progression using conventional imaging exams is challenging for clinicians during patient follow-up. Integrins, transmembrane proteins related to cell invasion and motility, are overexpressed in GB. This study evaluates the effects of [

Identifiers

PMID42812828
PMCPMC13622520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.